These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 34339975

  • 1. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR, Soni JY, Guduru R, Rayani RH, Kusurkar RV, Vala AG, Talukdar SN, Eissa IH, Metwaly AM, Khalil A, Zunjar V, Battula S.
    Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
    [Abstract] [Full Text] [Related]

  • 2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Oct; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 3. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM, El-Gaby MSA, El-Adl K, Abd El-Sattar NEA.
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [Abstract] [Full Text] [Related]

  • 4. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA, Abou-El-Regal MM, Eissa IH, Mehany ABM, Mahdy HA, Elkady H, Elwan A, Elkaeed EB.
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM, Taher FA, Abdel-Samad MRK, El-Gaby MSA, El-Adl K, Saleh NM.
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [Abstract] [Full Text] [Related]

  • 6. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM, Mahdy HA, Alsaif NA, Obaidullah AJ, Alkahtani HM, Al-Mehizia AA, Alsubaie SM, Dahab MA, Eissa IH.
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA, Abdel-Mohsen HT, El Kerdawy AM, Ragab FAF, Ali MM, Abu-Bakr SM, Girgis AS, El Diwani HI.
    Eur J Med Chem; 2017 Aug 18; 136():315-329. PubMed ID: 28505536
    [Abstract] [Full Text] [Related]

  • 8. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, Eissa IH.
    Bioorg Chem; 2021 Sep 18; 114():105105. PubMed ID: 34175720
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K, El-Helby AA, Sakr H, Ayyad RR, Mahdy HA, Nasser M, Abulkhair HS, El-Hddad SSA.
    Arch Pharm (Weinheim); 2021 Feb 18; 354(2):e2000279. PubMed ID: 33073374
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K, El-Helby AA, Sakr H, El-Hddad SSA.
    Arch Pharm (Weinheim); 2020 Aug 18; 353(8):e2000068. PubMed ID: 32510731
    [Abstract] [Full Text] [Related]

  • 11. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH.
    Arch Pharm (Weinheim); 2021 Mar 18; 354(3):e2000219. PubMed ID: 33197080
    [Abstract] [Full Text] [Related]

  • 12. New Thieno[2,3-d]pyrimidines as Anticancer VEGFR-2 Inhibitors with Apoptosis Induction: Design, Synthesis, and Biological and In Silico Studies.
    Sobh EA, Dahab MA, Elkaeed EB, Alsfouk BA, Ibrahim IM, Metwaly AM, Eissa IH.
    Med Chem; 2024 Mar 18; 20(9):876-899. PubMed ID: 38798211
    [Abstract] [Full Text] [Related]

  • 13. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK, Batran RZ, Elseginy SA, Ali MM, Mahmoud AE.
    Bioorg Chem; 2019 Apr 18; 85():253-273. PubMed ID: 30641320
    [Abstract] [Full Text] [Related]

  • 14. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH, El-Helby AA, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, El-Adl K.
    Bioorg Chem; 2020 Dec 18; 105():104380. PubMed ID: 33128967
    [Abstract] [Full Text] [Related]

  • 15. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H, Mahdy HA, Taghour MS, Dahab MA, Elwan A, Hagras M, Hussein MH, Ibrahim IM, Husein DZ, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH.
    Biochim Biophys Acta Gen Subj; 2024 Jun 18; 1868(6):130599. PubMed ID: 38521471
    [Abstract] [Full Text] [Related]

  • 16. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA, Abdel-Aziz SA, Abdelrahman KS, Wanas AS, Gouda AM, Youssif BGM, Abdel-Aziz M.
    Bioorg Chem; 2020 Sep 18; 102():104090. PubMed ID: 32683176
    [Abstract] [Full Text] [Related]

  • 17. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM, Hamdi A, Bayoumi WA, Elgazar AA, Nasr MNA.
    Bioorg Chem; 2024 Jul 18; 148():107437. PubMed ID: 38749114
    [Abstract] [Full Text] [Related]

  • 18. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies.
    Hagras M, Saleh MA, Ezz Eldin RR, Abuelkhir AA, Khidr EG, El-Husseiny AA, El-Mahdy HA, Elkaeed EB, Eissa IH.
    J Enzyme Inhib Med Chem; 2022 Dec 18; 37(1):380-396. PubMed ID: 34923885
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA, Naglah AM, Moustafa GO, Awad HM, El Kerdawy AM.
    Bioorg Med Chem Lett; 2022 Feb 15; 58():128529. PubMed ID: 35007724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.